Zobrazeno 1 - 10
of 3 918
pro vyhledávání: '"cabozantinib"'
Publikováno v:
European Thyroid Journal, Vol 13, Iss 6, Pp 1-7 (2024)
Objective: Poorly differentiated thyroid carcinomas (PDTCs) are rare and aggressive head and neck malignancies with a poor prognosis. Systemic treatment for incurable PDTC consists of multi-kinase inhibitors (MKIs) based on extrapolation from the exp
Externí odkaz:
https://doaj.org/article/c9efc544eace433cb1d56d670fcf23a3
Publikováno v:
Journal of Current Ophthalmology, Vol 36, Iss 1, Pp 103-106 (2024)
Purpose To describe the first reported instance of an acute chorioretinal inflammatory response to cabozantinib. Methods Case report. Results A 54-year-old Asian male presented with blurred vision 2 weeks following the commencement of cabozantinib fo
Externí odkaz:
https://doaj.org/article/4713be96dc86432b879f565778727d26
Publikováno v:
JAAD Case Reports, Vol 52, Iss , Pp 38-41 (2024)
Externí odkaz:
https://doaj.org/article/b70b79cbd6fd44cba6acb466b5330ea6
Autor:
Joel W. Neal, MD, PhD, Armando Santoro, MD, Maria Gonzalez-Cao, MD, PhD, Farah Louise Lim, MRCP, MD, Bruno Fang, MD, Ryan D. Gentzler, MD, MS, Jerome Goldschmidt, MD, Polina Khrizman, MD, Claudia Proto, MD, Shiven Patel, MD, MBA, FACP, Sonam Puri, MD, Stephen V. Liu, MD, Erminia Massarelli, MD, PhD, MS, Denise Williamson, MPH, Martin Schwickart, PhD, Christian Scheffold, MD, PhD, Svetlana Andrianova, MD, MPH, Enriqueta Felip, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 10, Pp 100666- (2024)
Introduction: We evaluated efficacy and safety of cabozantinib plus atezolizumab or cabozantinib alone in advanced NSCLC previously treated with an immune checkpoint inhibitor (ICI). Methods: COSMIC-021 (NCT03170960) is a phase 1b, multicenter study
Externí odkaz:
https://doaj.org/article/6812448f29344fa6a786793805d199c0
Autor:
Hironao Okubo, Hitoshi Ando, Shunsuke Nakamura, Yusuke Takasaki, Koichi Ito, Yuka Fukuo, Kenichi Ikejima, Hiroyuki Isayama
Publikováno v:
Cancer Medicine, Vol 13, Iss 18, Pp n/a-n/a (2024)
Abstract Aim To investigate the outcomes of cabozantinib in patients with unresectable hepatocellular carcinoma (uHCC), focusing on dose setting and modification. Methods We retrospectively analyzed 34 Japanese patients who received cabozantinib for
Externí odkaz:
https://doaj.org/article/bd189ccd8e1748df98a3f1cc1ca5db23
Publikováno v:
Clinical Case Reports, Vol 12, Iss 9, Pp n/a-n/a (2024)
Key Clinical Message Maintaining good medication adherence is important for providing desirable outcomes from medication therapy. We showed that therapeutic drug monitoring (TDM) contributed to the identification of low medication adherence to caboza
Externí odkaz:
https://doaj.org/article/933cc3a71a3c445894293ba3feeb62ff
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 7, Pp 100673- (2024)
Repotrectinib, licensed in November 2023, is a novel ROS1 tyrosine kinase inhibitor (TKI) with activity against G2032R, the most common resistance mutation to prior generations of ROS1 TKIs. Here, we report a case of a patient who was heavily pretrea
Externí odkaz:
https://doaj.org/article/7431ea6377e4481c94bd50a8012202bb
Autor:
Cristian Lolli, Antonio Verde, Luca Degli Esposti, Valentina Acciai, Alessia Brigido, Emanuela Proietti, Sarah Scagliarini
Publikováno v:
Global & Regional Health Technology Assessment, Vol 11, Iss 1 (2024)
Background: Cabozantinib use in everyday clinical practice for advanced or metastatic renal cell carcinoma (RCC) is relatively recent, and real-world data on treatment persistence, adherence and sequencing are still limited. Methods: We conducted an
Externí odkaz:
https://doaj.org/article/865fa36da71b4714ab07b497d096df32
Publikováno v:
Endocrine Oncology, Vol 3, Iss 1, Pp 1-16 (2024)
Objective: The treatment landscape for thyroid cancers has changed rapidly with the availability of kinase inhibitors against VEGFR, BRAF, MEK, NTRK, and RET. We provide an up-to-date review of the role of kinase inhibitors in thyroid cancer and disc
Externí odkaz:
https://doaj.org/article/6f623931aafc4aefafe091a5859235b3